Results 161 to 170 of about 5,542 (243)

Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. [PDF]

World J Gastroenterol
Kritzinger J, Candel I, Kotrri G, Nadeem H, Afif W, Bitton A, Wild G, Bessissow T, Lakatos PL.   +8 more
europepmc   +1 more source

Characterization of a Long-Acting Anti-Human MASP-2 Antibody for the Treatment of Complement-Related Diseases. [PDF]

J Inflamm Res
Han X, Yang C, Wang Z, Fan K, Liu K, Ye H, Zhang W, Zhang J, Hu X, Lin H, Liao C.   +10 more
europepmc   +1 more source

Will the emerging private-label market access channel help or hinder biosimilar market access? [PDF]

J Manag Care Spec Pharm
Mehr SR.
europepmc   +1 more source

Creating A Multi-Criteria Decision Analysis Tool to Enhance Value-Based Purchasing of Generic and Biosimilar Medications in Saudi Arabia: A Pilot Study. [PDF]

Clinicoecon Outcomes Res
Alruthia Y, Alhajri H, Almohammed OA, Balkhi B, Alsaqa'aby MF, Almuqbil MA, Al-Abdulkarim HA, Almutairi AR.   +7 more
europepmc   +1 more source

Efficacy & safety of adalimumab biosimilar in axial spondyloarthritis: A retrospective study from a tertiary care centre in South India. [PDF]

Indian J Med Res
Gopalan A, Gavali M, Yerram K.
europepmc   +1 more source

An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany. [PDF]

Front Public Health
Raitner I, Müller B, Vijayan A, Zimmermann L, Bramlage P, Ness NH, Müller M.   +6 more
europepmc   +1 more source

Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare Patients.

JAMA Netw Open
Riegler JS, Kesselheim AS, Rome BN.
europepmc   +1 more source

Comparative outcomes of aflibercept biosimilars and reference aflibercept in nAMD: a systematic review and meta-analysis. [PDF]

BMJ Open Ophthalmol
Sawires K, Nithianandan H, Somani S.
europepmc   +1 more source

HASH(0x563d440b87b0) [PDF]

, 2007
Groth, S.
core  

​Did a Non-Medical Biosimilar Switching Policy Cause an Increase in Non-Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis? [PDF]

Arthritis Care Res (Hoboken)
Dang H, Blitz S, Bansback N, Law M, Harrison M.   +4 more
europepmc   +1 more source